News Conference News EuroPCR 2024 TAVI, Surgery Look Similar Long-term Across Risk Spectrum: Meta-analysis Michael O'Riordan May 16, 2024
News Conference News EuroPCR 2024 Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids Michael O'Riordan May 15, 2024
News Conference News EuroPCR 2022 Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes Caitlin E. Cox May 17, 2022
News Conference News EuroPCR 2019 TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement Shelley Wood May 23, 2019
News Conference News EuroPCR 2019 Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats Michael O'Riordan May 22, 2019
Presentation EuroPCR 2018 Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies Presenter: E. Murat Tuzcu May 25, 2018
News Conference News EuroPCR 2018 Real-World Sapien 3 Results Match Trial Experience in Intermediate-Risk Patients Caitlin E. Cox May 25, 2018
News Conference News EuroPCR 2017 More Early Stroke With SAVR Than TAVR in SURTAVI Shelley Wood May 18, 2017
News Conference News EuroPCR 2016 ‘Obesity Paradox’ Alive, Well, and Mysterious After TAVR Yael L. Maxwell May 18, 2016
News Conference News EuroPCR 2015 NOTION: 2-Year Data Show Positive Outlook for TAVR in Lower-Risk Patients Yael L. Maxwell May 19, 2015
News Conference News EuroPCR 2014 New Iteration of Sapien Device Associated with Low Rates of Early Mortality, Stroke L.A. McKeown May 23, 2014